Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007781
Abstract: Key Points Ixazomib, cyclophosphamide, and dexamethasone combination achieved hematologic response in 63% of newly diagnosed AL amyloidosis patients. The regimen is characterized with a favorable adverse event profile and should be explored in other combinations. read more here.
Keywords: cyclophosphamide dexamethasone; trial ixazomib; ixazomib cyclophosphamide; phase trial ... See more keywords